Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 6Cisplatin 5Gemcitabine 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Hyperthermic Intraperitoneal Chemotherapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3veliparib 2aflibercept 2X-Rays 2Temozolomide 2Taxes 2SS1(dsFv)PE38 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Irinotecan 2Interleukin-12 Subunit p35 2Immunoglobulin G 2Gene Expression Profiling 2Fluorouracil 2Drug Therapy 2Doxorubicin 2Disulfides 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × BAY 1895344 × Gastrointestinal × Clear all
NCT04616534 2025-05-22

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
14 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡